Paroxysmal Nocturnal Hemoglobinuria: Clinicopathologic Features, Treatment, and Outcomes

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder with varying patient presentation. The pathophysiology is attributed to a mutation in the PIGA gene, causing deficiency in glycosylphosphatidylinositol (GPI)-anchored proteins on blood cells, increasing susceptibility to complement-mediated destruction. Diagnosis involves thorough clinical evaluation and laboratory testing including flow cytometry. Treatment options are varied, evolving, and dependent on disease severity. Patient response to therapy and disease monitoring requires regular lab assessments.

Lecture Presenter
Image
Adam Lyle, DO
Adam Lyle, DO
Pathology Resident, PGY 2, University of Utah School of Medicine

Dr. Adam Lyle earned his DO from Touro University California. Previously, he completed a BS in economics at Westminster College and had a career in finance.

Objectives

After this presentation, participants will be able to:

Explain the background of PNH, including history, epidemiology, and pathophysiology
Describe patient presentation, evaluation, and laboratory testing involved in diagnosing PNH
Discuss the classifications, treatment options, outcomes, and monitoring of PNH